Even though there are significant differences between the mentioned studies—mainly in terms of statistical analyses that have been used, selection of patients, and panel of studied markers—similarly to our study, Debes et al. identified increased circulating IL-4 and IL-13 levels in DAA-treated patients who later developed HCC when compared with controls. The gene discussed is IL4; the disease is hepatocellular carcinoma.